Sentry BioPharma Services ApS: Financial statements 2024
CVR: 41330619
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Sentry BioPharma Services ApS (CVR 41330619) has filed annual accounts for 2024. In 2024, the company reported a net result of DKK -3,275,518 compared with DKK -3,614,910 the year before. Equity in the 2024 report amounted to DKK -11,089,885.
- Profit/Loss
- DKK -3,275,518
- Equity
- DKK -11,089,885
- Total Assets
- DKK 4,647,363
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | -3.3 mio. | -11.1 mio. | - |
| 2023 | - | - | -3.6 mio. | -7.8 mio. | - |
| 2022 | - | - | -2.8 mio. | -4.2 mio. | - |
| 2021 | - | - | -1.1 mio. | -1.4 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of September 18, 2024, Ole Meier Sørensen has stepped down as director of Sentry BioPharma Services ApS.
Sentry BioPharma Services ApS has published its annual report for 2023. The net result was DKK -3,614,910.
About Sentry BioPharma Services ApS
Sentry BioPharma Services ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company is registered under the industry Oplagring og opbevaring. The management consists of Timothy Jon Mitchell and William Maxwell Tuttle. The company is owned by Sentry BioPharma Services, Inc.. The company has 1 employee (2026). In 2025, the company reported a net result of DKK -537,511 compared with DKK -3,275,518 the year before. Equity in the 2025 report amounted to DKK -11,627,396.